anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Genelux · pitchdeck

Genelux | Investor Presentation Deck | 38 slides

38 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Genelux | Investor Presentation Deck | 38 slides

Genelux · 2023-07
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 10 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 3 slides 100% 3/3 slides 100% 3/3 slides · 16 hits
— 0/3 slides
33.3% 1/3 slides 66.7% 2/3 slides 100% 3/3 slides
— 0/3 slides
Solution 3 slides 100% 3/3 slides 100% 3/3 slides · 14 hits
— 0/3 slides
— 0/3 slides
100% 3/3 slides 100% 3/3 slides
— 0/3 slides
Market Size 2 slides 100% 2/2 slides 100% 2/2 slides · 12 hits
— 0/2 slides
50% 1/2 slides
— 0/2 slides
100% 2/2 slides
— 0/2 slides
Team 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
— 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides
— 0/2 slides

Slide inventory

38
every slide · same image gating as the playbook
01
Slide 1
Includes company logo and tagline.front_matter
Open slide detail
02
other
Open slide detail
03
summarize
Open slide detail
04
present_solution
Open slide detailBeat · Problem
05
The slide uses a Gantt-style visualization to map drug development progress against clinical phases.plan_implementation
Open slide detailBeat · Problem
06
Uses a process diagram to illustrate the transition from cold to hot tumor states.present_solution
Open slide detailBeat · Problem
07
The central diagram illustrates the biological mechanism of action, contrasting the absence vs. presence of effector T cells.present_solution
Open slide detailBeat · Solution
08
The slide uses a timeline to establish market validation through historical M&A and financing events.show_traction
Open slide detailBeat · Solution
09
The slide uses a list-based comparison and a logo-grid to frame the competitive landscape.compare_peers
Open slide detailBeat · Solution
10
The slide uses a pyramid diagram to represent the evolution of oncolytic virus technology, with Genelux's platform at the top.present_solution
Open slide detail
11
The slide uses a document-style container for patient background and icon-based lists for clinical outcomes.show_traction
Open slide detail
12
The slide uses a process-flow layout to show the trial design and its downstream impact (publications and Phase 3).show_traction
Open slide detailLoop · Cost Of Inaction
13
Data table presents ORR, Duration of Response, CA-125 response, PFS, and OS across patient subgroups.show_traction
Open slide detailLoop · Cost Of Inaction
14
Includes a spider plot (tumor shrinkage over time) and a waterfall plot (duration of response).show_traction
Open slide detailLoop · Cost Of Inaction
15
The slide uses a series of bar charts to compare PFS across multiple treatment regimens for three specific patients (15B-01, 15B-15, 15B-17).show_traction
Open slide detailLoop · Cost Of Inaction
16
Kaplan-Meier survival curve showing patient outcomes.show_traction
Open slide detail
17
The slide uses a cross-trial comparison to highlight the efficacy of Olvi-Vec in heavily pre-treated patients compared to other standard regimens.summarize
Open slide detail
18
The slide outlines a randomized, open-label trial comparing Olvi-Vec + Platinum-doublet + Bevacizumab against a standard comparator arm.plan_implementation
Open slide detailLoop · Quick Win Big Bet
19
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.show_traction
Open slide detailLoop · Quick Win Big Bet
20
Includes two specific patient case studies with longitudinal data and RECIST response metrics.show_traction
Open slide detailLoop · Quick Win Big Bet
21
Includes a bio for Benny Li, PhD, CEO of Newsoara.show_traction
Open slide detail
22
The table outlines a strategic partnership involving funding and regional commercialization rights.show_traction
Open slide detail
23
The slide highlights a combination therapy approach using two distinct technologies with separate clinical trial data.summarize
Open slide detail
24
Includes a map of the US as a background element, likely to denote the geographic scope of the market sizing.size_opportunity
Open slide detailBeat · Market Size
25
The slide highlights physical assets and operational capacity.present_solution
Open slide detailBeat · Market Size
26
The slide uses a hub-and-spoke style layout to show the four pillars supporting the central launch strategy.plan_implementation
Open slide detail
27
The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies.present_solution
Open slide detail
28
present_solution
Open slide detail
29
other
Open slide detailBeat · Team
30
The slide uses a split layout: a list for past achievements and an arrow-based timeline for future goals.show_traction
Open slide detailBeat · Team
31
Includes footnotes regarding reconciliation of cap table and specific financing commitments.analyze_data
Open slide detail
32
show_traction
Open slide detail
33
appendix
Open slide detail
34
The slide highlights the credibility of the advisory board through their affiliations with major cancer research organizations and clinical trial experience.other
Open slide detail
35
Includes microscopic imagery of patient samples (Pt.#15A-01 and Pt.#15A-11) showing longitudinal progression of treatment.show_traction
Open slide detail
36
The slide uses a before-and-after comparison of histology images and corresponding infiltration histograms to demonstrate drug efficacy.show_traction
Open slide detail
37
Includes a clinical case study (Pt #15A-05) with ELISPOT data and longitudinal tumor lesion size tracking.show_traction
Open slide detail
38
The slide uses clinical study data (VIRO-15, NCT01443260) to support its claims about immune modulation.present_solution
Open slide detail